

7 FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 0609.4440002	APPLICATION NO. 09/394,712
	APPLICANT ESMOND <i>et al.</i>	
	FILING DATE Sept. 13, 1999	GROUP 1614

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
57 6	AA7	5,457,109	10/10/95	Antonucci <i>et al.</i>	514	252	8/23/94
	AB7	5,478,852	12/26/95	Olefsky <i>et al.</i>	514	369	8/23/94
	AC7						
	AD7						
	AE7						
	AF7						
	AG7						
	AH7						
	AI7						
	AJ7						
	AK7						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL7						Yes No
	AM7						Yes No
	AN7						Yes No
	AO7						Yes No
	AP7						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
5	AR	Z	Combs, C.K. <i>et al.</i> . "Inflammatory Mechanisms in Alzheimer's Disease: Inhibition of β -Amyloid-Stimulated Proinflammatory Responses and Neurotoxicity by PPAR γ Agonists," <i>J. Neurosci.</i> 20:558-567 (2000)
6	AS	Z	Hulin, B. <i>et al.</i> . "Novel Thiazolidine-2,4-diones as Potent Euglycemic Agents," <i>J. Med. Chem.</i> 35:1853-1864 (1992)
7	AT	Z	Wilson, T. M. <i>et al.</i> . "The PPARs: From Orphan Receptors to Drug Discovery," <i>J. Med. Chem.</i> 43:527-550 (2000)

EXAMINER	DATE CONSIDERED 8/30/00
----------	-------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

8 FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 0609.4440002	APPLICATION NO. 09/394,712
	APPLICANT ESMOND <i>et al.</i>	
	FILING DATE Sept. 13, 1999	GROUP 1614

U.S. PATENT DOCUMENTS							
EXAMINER-INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA5						
	AB5						
	AC5						
	AD5						
	AE5						
	AF5						
	AG5						
	AH5						
	AI5						
	AJ5						
	AK5						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL5						Yes No
	AM5						Yes No
	AN5						Yes No
	AO5						Yes No
	AP5						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
	AR	5	
	AS	5	
✓	AT	5	Bernstein, H.G. <i>et al.</i> , "Insulin-degrading enzyme in the Alzheimer's disease brain: prominent localization in neurons and senile plaques," <i>Neurosci. Lett.</i> 263:161-4 (1999)

EXAMINER	DATE CONSIDERED 8/3/02
----------	------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

a FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 0609.4440002	APPLICATION NO. 09/394,712
	APPLICANT ESMOND <i>et al.</i>	
	FILING DATE Sept. 13, 1999	GROUP 1614

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA6						
	AB6						
	AC6						
	AD6						
	AE6						
	AF6						
	AG6						
	AH6						
	AI6						
	AJ6						
	AK6						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL6						Yes No
	AM6						Yes No
	AN6						Yes No
	AO6						Yes No
	AP6						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	6	Blum-Degan, D. <i>et al.</i> , "Altered regulation of brain glucose metabolism as a cause of neurodegenerative disorders?," <i>J. Neural Transm. Suppl.</i> 46:139-47 (1995)
	AS	6	Craft, S. <i>et al.</i> , "Memory improvement following induced hyperinsulinemia in Alzheimer's disease," <i>Neurobiol. Aging</i> 17:123-30 (1996)
	AT	6	Craft, S. <i>et al.</i> , "Enhancement of memory in Alzheimer disease with insulin and somatostatin, but not glucose," <i>Arch. Gen. Psychiatry</i> 56:1135-40 (1999)

EXAMINER	DATE CONSIDERED 8/30/00
----------	-------------------------




EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.


10 FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 0609.4440002	APPLICATION NO. 09/394,712
	APPLICANT ESMOND <i>et al.</i>	
	FILING DATE Sept. 13, 1999	GROUP 1614

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA7						
	AB7						
	AC7						
	AD7						
	AE7						
	AF7						
	AG7						
	AH7						
	AI7						
	AJ7						
	AK7						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL7						Yes No
	AM7						Yes No
	AN7						Yes No
	AO7						Yes No
	AP7						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	Z	Craft, S. <i>et al.</i> , "Cerebrospinal fluid and plasma insulin levels in Alzheimer's disease: relationship to severity of dementia and apolipoprotein E genotype," <i>Neurology</i> 50:164-8 (Jan. 1998)
	AS	Z	Frolich, L. <i>et al.</i> , "Brain insulin and insulin receptors in aging and sporadic Alzheimer's disease," <i>J. Neural Transm.</i> 105:423-38 (1998)
	AT	Z	Gambassi, G. and Bernabei, R., "Insulin, diabetes mellitus, Alzheimer's disease and apolipoprotein E," <i>Neurology</i> 51:925-6 (Sept. 1998)

EXAMINER 	DATE CONSIDERED 8/30/00
--	-------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449


INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
0609.4440002APPLICATION NO.
09/394,712APPLICANT
ESMOND *et al.*FILING DATE
Sept. 13, 1999

GROUP 1614

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA8						
	AB8						
	AC8						
	AD8						
	AE8						
	AF8						
	AG8						
	AH8						
	AI8						
	AJ8						
	AK8						



FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL8						Yes No
	AM8						Yes No
	AN8						Yes No
	AO8						Yes No
	AP8						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)


	AR	8	Heitner, J. and Dickson, D., Diabetics do not have increased Alzheimer-type pathology compared with age-matched control subjects. A retrospective postmortem immunocytochemical and histofluorescent study, <i>Neurology</i> 49:1306-11 (Nov. 1997)
	AS	8	Holden, R.J., and Mooney, P.A., "Interleukin-1 β : a common cause of Alzheimer's Disease and Diabetes Mellitus," <i>Med. Hypothesis</i> 45:559-71 (1995)
	AT	8	Hoyer, S., <i>et al.</i> , "Desensitization of brain insulin receptor. Effect on glucose/energy and related metabolism," <i>J. Neural Transm. Suppl.</i> 44:259-68 (1994)

EXAMINER


DATE CONSIDERED

8/30/00

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.




 <p>FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT</p>	ATTY. DOCKET NO. 0609.4440002	APPLICATION NO. 09/394,712
	APPLICANT ESMOND <i>et al.</i>	
	FILING DATE Sept. 13, 1999	GROUP 1614


U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA9						
	AB9						
	AC9						
	AD9						
	AE9						
	AF9						
	AG9						
	AH9						
	AI9						
	AJ9						
	AK9						



FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL9						Yes No
	AM9						Yes No
	AN9						Yes No
	AO9						Yes No
	AP9						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	2	Hoyer, S., "Oxidative metabolism deficiencies in brains of patients with Alzheimer's disease," <i>Acta Neurol. Scand. Suppl.</i> 165:18-24 (1996)
	AS	2	Hoyer, S., "Models of Alzheimer's disease: cellular and molecular aspects," <i>J. Neural. Transm. Suppl.</i> 49:11-21 (1997)
	AT	2	Hoyer, S., "Is sporadic Alzheimer disease of the brain type of non-insulin dependent diabetes mellitus? A challenging hypothesis," <i>J. Neural Transm.</i> 105:415-22 (1998)

EXAMINER 	DATE CONSIDERED 8/30/00
--	-------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

<div style="font-size: 2em; margin-bottom: 10px;">13</div> <div style="text-align: center;">FORM PTO-1449</div> <div style="text-align: center;"><u>INFORMATION DISCLOSURE STATEMENT</u></div>	ATTY. DOCKET NO. 0609.4440002	APPLICATION NO. 09/394,712
	APPLICANT ESMOND <i>et al.</i>	
	FILING DATE Sept. 13, 1999	GROUP 1614

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA10						
	AB10						
	AC10						
	AD10						
	AE10						
	AF10						
	AG10						
	AH10						
	AI10						
	AJ10						
	AK10						

O I P E J C I 2

FEB 25 2000

PATENT & TRADEMARK OFFICE

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL10						Yes No
	AM10						Yes No
	AN10						Yes No
	AO10						Yes No
	AP10						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

f	AR	10	Kuusisto, J. <i>et al.</i> , "Association between features of the insulin resistance syndrome and Alzheimer's disease independently of the apolipoprotein E4 phenotype: cross sectional population based study," <i>BMJ</i> 315:1045-9 (Oct. 1997)
k	AS	10	Lithner, F., "Diabetes and Alzheimer's disease," <i>Diabetologia</i> 39:1242 (1996)
v	AT	10	Vanhanen, M. and Soininen, H., "Glucose intolerance, cognitive impairment and Alzheimer's disease," <i>Curr. Opin. Neurol.</i> 11:673-7 (Dec. 1998)

EXAMINER 	DATE CONSIDERED 8/30/02
--	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.


149 FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 0609.4440002	APPLICATION NO. 09/394,712
	APPLICANT ESMOND <i>et al.</i>	
	FILING DATE Sept. 13, 1999	GROUP 1614

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA11						
	AB11						
	AC11						
	AD11						
	AE11						
	AF11						
	AG11						
	AH11						
	AI11						
	AJ11						
	AK11						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL11						Yes No
	AM11						Yes No
	AN11						Yes No
	AO11						Yes No
	AP11						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

15	AR	11	Yanagisawa, M. <i>et al.</i> , "Starvation induces tau hyperphosphorylation in mouse brain: implications for Alzheimer's disease," <i>FEBS Lett.</i> 461:329-33 (1999)
	AS	11	
	AT	11	

EXAMINER 	DATE CONSIDERED 8/30/00
---	----------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.